Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

As Life Sciences Work Heats Up, Goodwin Brings On Partner (<em>The American Lawyer</em>)

As Life Sciences Work Heats Up, Goodwin Brings On Partner (The American Lawyer)

Related Content

FDA to Phase Out Animal Testing for Monoclonal Antibodies and Other Drugs

Life Sciences Companies Must Navigate the DOJ Data Rule

FDA Approves Biocon Biologics’ Bevacizumab Biosimilar

Teva and Samsung Bioepis Announce U.S. Launch of EPYSQLI® (eculizumab-aagh), a SOLIRIS® Biosimilar

GSK and Pfizer Stipulate to Dismissal of RSV Vaccines Lawsuit

EMA Seeks Input on a “Tailored Clinical Approach” in Biosimilar Development

Accord Receives Positive EMA Opinion for Two Denosumab Biosimilars

Global Biosimilar Updates – Spring 2025

Radiopharmaceuticals M&A to go Nuclear over Production Demand, Novel Drugs (Mergermarket)

Boston Forum: Merger Control & Competition in Life Sciences

Goodwin Is Top Law Firm for Global M&A for Q1 2025

Goodwin’s Annual Healthcare & Life Sciences Summit

AI Valuations ‘Miles Ahead of’ Regular Tech, Says Goodwin Panel; Spring Statement Gives ‘Greater Confidence’ to Defense Investors (PE HUB)

The Legal 500 EMEA 2025 Recognizes Goodwin for Excellence Across Europe

Goodwin Advised Harbour BioMed in $175 Million Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Therapeutic Antibodies

Leading the Charge in Life Sciences Litigation, Goodwin is Shortlisted For Three Managing IP Awards

Life Sciences

Intellectual Property

Litigation